5Alarmbio Babraham Research Lab Dr. William Bains � small molecule drug


In February 2022 Five Alarm Bio (FAB) won a grant worth £360,000 from InnovateUK’s prestigious Biomedical Catalyst program.  In March of 2022 FAB, in collaboration with Magnitude Biosciences, tested its technology on nematodes.  Magnitude showed that Five Alarm Bio’s test compound improved the healthspan of the worms by about 40%, making a 5-day old worm move as easily as a 3¾ day old worm. In July 2022 FAB appointed Dr. Janette Thomas as CEO. In October of 2022 FAB began research on the Babraham Research Campus, near Cambridge, England.